Nom du produit:(R)-6-tert-Butyl 4a-methyl 1-(4-fluorophenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isoquinoline-4a,6(4H)-dicarboxylate

IUPAC Name:6-tert-butyl 4a-methyl (4aR)-1-(4-fluorophenyl)-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f]indazole-4a,6-dicarboxylate

CAS:864972-21-4
Formule moléculaire:C23H26FN3O4
Pureté:97%
Numéro de catalogue:CM227405
Poids moléculaire:427.48

Unité d'emballage Stock disponible Prix($) Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:864972-21-4
Formule moléculaire:C23H26FN3O4
Point de fusion:-
Code SMILES:O=C([C@]12CC3=C(N(C4=CC=C(F)C=C4)N=C3)C=C1CCN(C(OC(C)(C)C)=O)C2)OC
Densité:
Numéro de catalogue:CM227405
Poids moléculaire:427.48
Point d'ébullition:
N° Mdl:
Stockage:

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.